Message #10 From:
NewsBot Date: December 12, 2006 04:00:00 AM
PKTX News ProtoKinetix' AAGP(TM) Doubles Viability of Cryopreserved Stem Cells
VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix, Inc. (OTCBB:PKTX)announces further confirmation of
AAGP™ effectiveness in the cryopreservation of
sensitive cells. Recent tests were completed by ITTEC Stem Inc., of
Laval, Quebec, comparing cryopreservation techniques on mouse Embryonic
Stem (ES) cells using the standard Dimethyl Sulfoxide (DMSO) as a
control group against the combination of DMSO with AAGP™.
Cell viabilities were evaluated after rapid thawing in a 37°C
water bath for 1 to 2-minutes after 2-days of freezing at -80°C.
A concentration of 8.6mM AAGP™ significantly
increased stem cell viability when added in combination with 10% DMSO.
As compared to the control group using 10% DMSO, the addition of AAGP™
to the delicate stem cells during cryopreservation procedures increased
the thawed out cell viability by over 100%. This enormous increase in
yield has dramatic implications for the medical, pharmaceutical and
research industries.
About ProtoKinetix:
ProtoKinetix Inc is a Biotechnical Company dedicated to the development
of a family of synthetic antifreeze glycoproteins (AAGP™)
for human and veterinary medicine, the bio technology and cosmetic
industries. Using previously published research on native antifreeze
proteins and antifreeze glycoproteins as a guide, and coordinating a
vast pool of world recognized intellectual talent in a networked
environment, PKTX is conducting rapid and meaningful research with a
view to developing markets for this very useful family of molecules.
Sign up for free automatic email news alerts at our new website at: www.protokinetix.com.
The Private Securities Litigation Reform Act of 1995 provides a “safe
harbor” for forward-looking statements. Some
information included in this press release contains statements that are
forward-looking. Such forward-looking information involves significant
risks and uncertainties that could affect anticipated results in the
future and, accordingly, these results may differ materially from those
expressed in any forward-looking statements made by or on behalf of the
Company. For a description of additional risks and uncertainties, please
refer to the Company’s filings with the
Securities and Exchange Commission.
On behalf of the Board of Directors
Dr. John Todd -- President
Company Office:
Suite # 1500
885 West Georgia Street
Vancouver, BC V6C 3E8
